The Algerian Secretary-General of the Ministry of Health, Abdelkrim Bendjemil, received a delegation from the African Union Commission on 31 March 2026, according to الإذاعة الجزائرية. The meeting focused on strengthening local pharmaceutical manufacturing, a sector that has seen steady growth in Algeria over the past five years.
Algeria’s pharmaceutical industry currently produces around 60% of the country’s drug needs, up from 45% in 2020, according to ministry data. The sector includes 18 state-approved manufacturing plants, with an additional 12 under construction or in the licensing phase. These facilities are concentrated in industrial zones near Algiers, Oran, and Constantine, where infrastructure and logistics networks are most developed.
The African Union delegation, led by Commissioner for Health, Humanitarian Affairs and Social Development Minata Samate Cessouma, discussed potential partnerships under the African Medicines Agency (AMA) framework. The AMA, headquartered in Algeria since 2024, aims to harmonise drug regulations across the continent and boost intra-African pharmaceutical trade. Algeria’s role as host positions it as a potential hub for drug exports to sub-Saharan markets, where demand for affordable generics is rising.
For Algerian entrepreneurs, the meeting signals two immediate opportunities. First, the Ministry of Health has indicated plans to streamline approval processes for locally manufactured drugs, reducing the average waiting time for new product registrations from 18 months to 12 months. This change, expected to take effect in late 2026, could accelerate market entry for startups in the generics and biosimilars space.
Second, the African Union’s focus on technology transfer and joint ventures opens doors for Algerian firms to collaborate with international pharmaceutical companies. The Ministry of Health has already identified three priority areas for investment: active pharmaceutical ingredients (APIs), vaccines, and medical devices. API production, in particular, remains a bottleneck for Algeria, with over 80% of raw materials currently imported from India and China. Localising API manufacturing could reduce production costs by up to 30%, according to industry estimates.
The Algerian diaspora, which includes an estimated 20,000 professionals in the healthcare and pharmaceutical sectors, stands to benefit from these developments. The government has introduced incentives for diaspora investors, including tax exemptions on reinvested profits and simplified procedures for setting up businesses in Algeria’s pharmaceutical free zones. These zones, located in Sidi Abdallah (Algiers) and Hassi Messaoud, offer customs duty waivers on imported equipment and raw materials.
Challenges remain, however. Algeria’s pharmaceutical market is valued at approximately $3.5 billion annually, but only 15% of local manufacturers export their products, primarily to neighbouring Maghreb countries. Scaling up production for African markets will require upgrades to quality control systems to meet international standards, such as the World Health Organization’s Good Manufacturing Practices (GMP). The Ministry of Health has allocated $120 million in public funds to support GMP certification for local plants, with a target of certifying 10 additional facilities by 2028.
The meeting also touched on the role of digital health in expanding access to medicines. Algeria’s National Agency for Pharmaceutical Products (ANPP) has begun piloting a blockchain-based system for tracking drug distribution, aimed at reducing counterfeit medicines. Entrepreneurs in the health tech sector could leverage this infrastructure to develop supply chain solutions for African markets.
Key takeaway for entrepreneurs
Algeria’s pharmaceutical sector is entering a phase of regulatory acceleration and regional expansion, with faster drug approvals and new export opportunities under the African Medicines Agency. Diaspora investors and local startups can target gaps in API production, vaccines, and medical devices, supported by tax incentives and public funding for quality certifications. The focus on digital health also creates openings for tech-driven supply chain and distribution solutions.
💡 Starting a business in Algeria? GlobalStart guides you step by step: procedures, real costs, company forms (SARL, EURL, SPA) and CNRC registration.